CHAPTER 22: CODES FOR SPECIAL PURPOSES (U00-U85)

This chapter contains the following blocks:
U00-U49  Provisional assignment of new diseases of uncertain etiology or emergency use

Provisional assignment of new diseases of uncertain etiology or emergency use (U00-U49)

- **U07**  Emergency use of U07
  - **U07.0**  Vaping-related disorder
    - Dabbing related lung damage
    - Dabbing related lung injury
    - E-cigarette, or vaping, product use associated lung injury [EVALI]
    - Electronic cigarette related lung damage
    - Electronic cigarette related lung injury

Use additional code to identify manifestations, such as:
- abdominal pain (R10.84)
- acute respiratory distress syndrome (J80)
- diarrhea (R19.7)
- drug-induced interstitial lung disorder (J70.4)
- lipid pneumonia (J80.1)
- weight loss (R63.4)

**GUIDELINES**

Section I.C.10.e.
For patients presenting with condition(s) related to vaping, assign code U07.0. Vaping-related disorder, as the principal diagnosis. For lung injury due to vaping, assign only code U07.0. Assign additional codes for other manifestations, such as acute respiratory failure (subcategory J96.0-) or pneumonitis (code J68.0).

Associated respiratory signs and symptoms due to vaping, such as cough, shortness of breath, etc., are not coded separately, when a definitive diagnosis has been established. However, it would be appropriate to code separately any gastrointestinal symptoms, such as diarrhea and abdominal pain.

**DEFINITION**
E-cigarette or vaping product use associated lung injury (EVALI) is the lung disease linked to vaping. Symptoms include cough, shortness of breath, acute respiratory distress, chest pain, fever, stomach pain, diarrhea, nausea, vomiting and weight loss. Damaging lung effects can be so severe as to stop the lungs from functioning. It is thought that vitamin E acetate or other harmful chemical byproduct produced by the heated liquid disrupt the lung’s surfactant lining or otherwise interferes with the lung’s ability to expand. Treatment includes the use of a ventilator or supplemental oxygen depending on illness severity; corticosteroids to reduce inflammation; and antibiotics or antivirals until test results for EVALI are finalized.

AHA: 1Q 2020, 3

- **U07.1**  COVID-19
  - Use additional code to identify pneumonia or other manifestations

**EXCLUDES 1**
- coronavirus infection, unspecified (B34.2)
- coronavirus as the cause of diseases classified elsewhere (B97.2-)
- pneumonia due to SARS-associated coronavirus (J12.81)

**GUIDELINES**

Section I.C.1.g.1)(g)
For patients presenting with any signs/symptoms associated with COVID-19 (such as fever, etc.) but a definitive diagnosis has not been established, assign the appropriate code(s) for each of the presenting signs and symptoms such as:
- R05 (Cough)
- R06.02 (Shortness of breath)
- R50.9 (Fever, unspecified).

If a patient with signs/symptoms associated with COVID-19 also has an actual or suspected contact with or exposure to someone who has COVID-19, assign Z20.828. Contact with and (suspected) exposure to other viral communicable diseases, as an additional code.